Risk of Psoriasis Following Terbinafine or Itraconazole Treatment for Onychomycosis: A Population-Based Case-Control Comparative Study

Hsien-Yi Chiu (), Wei-Lun Chang (), Tsen-Fang Tsai (), Yi-Wen Tsai () and Ming-Neng Shiu ()
Additional contact information
Hsien-Yi Chiu: National Taiwan University
Wei-Lun Chang: National Yang-Ming University
Tsen-Fang Tsai: National Taiwan University Hospital and National Taiwan University College of Medicine
Yi-Wen Tsai: National Yang-Ming University
Ming-Neng Shiu: National Yang-Ming University

Drug Safety, 2018, vol. 41, issue 3, No 5, 285-295

Abstract: Abstract Introduction Several case studies have reported an association between antifungal drug use and psoriasis risk. Objective The objective of this study was to investigate the association between terbinafine/itraconazole exposure and psoriasis incidence. Methods Among patients with onychomycosis in the Taiwan National Health Insurance Research Database, 3831 incident psoriasis cases were identified during 2004–2010 and compared with 3831 age- and sex-matched controls with the same look-back period. Multivariate conditional logistic regression was used for the analysis. Results The psoriasis cases were significantly more likely than matched controls to have used terbinafine or itraconazole (59.85 vs. 42.70%, respectively; p 360 days). In a comparison of patients receiving terbinafine or itraconazole only, psoriasis risk was higher for itraconazole (adjusted odds ratio 1.21, 95% confidence interval 1.05–1.40). Conclusion This large population-based case-control analysis showed that exposure to terbinafine or itraconazole is associated with an increased risk of incident psoriasis. The finding of an increased psoriasis risk for antifungal drug users, particularly for itraconazole, deserves attention in clinical practice although further prospective studies are necessary to confirm our findings and clarify the biological mechanisms that underlie these associations.

Date: 2018
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-017-0614-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:41:y:2018:i:3:d:10.1007_s40264-017-0614-2

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-017-0614-2

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().